ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

被引：3
|
作者：
Moscetti, Luca [1 ,7 ]
Mentuccia, Lucia [2 ]
Vici, Patrizia [3 ]
Quadrini, Silvia [2 ]
Sperduti, Isabella [4 ]
Pizzuti, Laura [3 ]
Fabbri, Maria Agnese [1 ]
Vaccaro, Angela [2 ]
Sacca, Marcello Maugeri [3 ,6 ]
Barba, Maddalena [3 ,6 ]
Sergi, Domenico [3 ]
Zampa, Germano [5 ]
Gamucci, Teresa [2 ]
机构：
[1] Belcolle Hosp, AUSL Viterbo, Div Med Oncol, Viterbo, Italy
[2] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[3] Regina Elena Inst Canc Res, Div Med Oncol B, Rome, Italy
[4] Regina Elena Inst Canc Res, Biostat, Rome, Italy
[5] Nuovo Regina Margherita Hosp, Med Oncol Unit, Rome, Italy
[6] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy
[7] Azienda Osped Univ Policlin Modena, Dept Oncol & Hematol, Modena, Italy
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 17期
关键词：
Edmonton symptoms assessment scale; eribulin mesylate; metastatic breast cancer; quality of life; QUALITY-OF-LIFE; CAPECITABINE; MESYLATE; SCALE;
D O I：
10.2217/fon-2017-0062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations. Patients & methods: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires. Results: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores. Conclusion: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.
引用
收藏
页码：1517 / 1525
页数：9
相关论文
共 50 条
  • [21] Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)
    Ohtani, Shoichiro
    Nakayama, Takahiro
    Yoshinami, Tetsuhiro
    Watanabe, Ken-ichi
    Hara, Fumikata
    Sagara, Yasuaki
    Kawaguchi, Hidetoshi
    Higaki, Kenji
    Matsunami, Nobuki
    Hasegawa, Yoshie
    Takahashi, Masato
    Mizutani, Makiko
    Morimoto, Takashi
    Sato, Masako
    Itoh, Mitsuya
    Morita, Satoshi
    Masuda, Norikazu
    [J]. BREAST CANCER, 2018, 25 (04) : 438 - 446
  • [22] Multicenter study of the eValuation of Eribulin (E) use in Sicily in metastatic breast cancer (MBC): A Prospective RegistrY (VESPRY trial)
    Adamo, V.
    Ricciardi, G. R. R.
    Franchina, V.
    Ferraro, G.
    Caruso, M.
    Bronte, G.
    Banna, G. L.
    Spadaro, P.
    Savarino, A.
    Iacono, C.
    Parra, H. J. Soto
    Spada, M.
    Safina, V.
    Blasi, L.
    Zerilli, F.
    Prestifilippo, A.
    Giannitto-Giorgio, C.
    Alberio, D.
    Cottini, L.
    Russo, A.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 20 - 20
  • [23] Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer
    Chonghua Wan
    Dongmei Zhang
    Zheng Yang
    Xin Tu
    Wan Tang
    Changyong Feng
    Hongyue Wang
    Xueliang Tang
    [J]. Breast Cancer Research and Treatment, 2007, 106
  • [24] Multicenter study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).
    Adamo, Vincenzo
    Ricciardi, Giuseppina
    Giuffrida, Dario
    Scandurra, Giuseppa
    Russo, Antonio
    Blasi, Livio
    Spadaro, Pietro
    Lucenti, Antonio
    Parra, Hector J. Soto
    Savarino, Antonino
    Ferrau, Francesco
    Zerilli, Filippo
    Verderame, Francesco
    Butera, Alfredo
    Franchina, Veronica
    Cottini, Lorenzo
    Fedele, Guido
    Caruso, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Vahdat, Linda T.
    Pruitt, Brian
    Fabian, Carol J.
    Rivera, Ragene R.
    Smith, David A.
    Tan-Chiu, Elizabeth
    Wright, Jonathan
    Tan, Antoinette R.
    DaCosta, Noshir A.
    Chuang, Ellen
    Smith, John
    O'Shaughnessy, Joyce
    Shuster, Dale E.
    Meneses, Nicole L.
    Chandrawansa, Kumari
    Fang, Fang
    Cole, Patricia E.
    Ashworth, Simon
    Blum, Joanne L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2954 - 2961
  • [26] Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
    Jacot, William
    Heudel, Pierre-Etienne
    Fraisse, Julien
    Gourgou, Sophie
    Guiu, Severine
    Dalenc, Florence
    Pistilli, Barbara
    Campone, Mario
    Levy, Christelle
    Debled, Marc
    Leheurteur, Marianne
    Chaix, Marie
    Lefeuvre, Claudia
    Goncalves, Anthony
    Uwer, Lionel
    Ferrero, Jean-Marc
    Eymard, Jean-Christophe
    Petit, Thierry
    Mouret-Reynier, Marie-Ange
    Courtinard, Coralie
    Cottu, Paul
    Robain, Mathieu
    Mailliez, Audrey
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (12) : 3359 - 3369
  • [27] MEASUREMENT PROPERTIES OF THE ENGLISH AND CHINESE VERSIONS OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY - BREAST (FACT-B) IN ASIAN BREAST CANCER PATIENTS
    Ng, R.
    Lee, C. F.
    Wong, N. S.
    Luo, N.
    Yap, Y. S.
    Lo, S. K.
    Chia, J.
    Yee, A.
    Krishna, L.
    Goh, C.
    Cheung, Y. B.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A461 - A461
  • [28] Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study
    Yardley, Denise A.
    Reeves, James
    Dees, E. Claire
    Osborne, Cynthia
    Pau, Devchand
    Ademuyiwa, Foluso
    Soliman, Hatem
    Guthrie, Troy
    Andersen, Jay
    Krekow, Lea
    Choksi, Janak
    Daniel, Brooke
    Danso, Michael
    Favret, Anne
    Oommen, Sanjay
    Brufsky, Adam
    Bromund, Jane L.
    Lin, Yong
    Ibrahim, Ayman B.
    Richards, Paul D.
    [J]. CLINICAL BREAST CANCER, 2016, 16 (06) : 471 - 479
  • [29] Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A realworld evidence study from China
    Yan, Xi
    Chen, Lan
    He, Ping
    Tian, Ting-Lun
    Zhong, Xiaorong
    Luo, Ting
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301
    Kaufman, P. A.
    Yelle, L.
    Cortes, J.
    Perez, E. A.
    Awada, A.
    Wanders, J.
    Olivo, M. S.
    Dutcus, C. E.
    Twelves, C.
    [J]. CANCER RESEARCH, 2013, 73
12345